key: cord-0937559-7bvviylj authors: Wan, Suxin; Xiang, Yi; Fang, Wei; Zheng, Yu; Li, Boqun; Hu, Yanjun; Lang, Chunhui; Huang, Daoqiu; Sun, Qiuyan; Xiong, Yan; Huang, Xia; Lv, Jinglong; Luo, Yaling; Shen, Li; Yang, Haoran; Huang, Gu; Yang, Ruishan title: Clinical features and treatment of COVID‐19 patients in northeast Chongqing date: 2020-04-01 journal: J Med Virol DOI: 10.1002/jmv.25783 sha: 3d74fe714e3ff1217e6ba2ac689d09a2c425d417 doc_id: 937559 cord_uid: 7bvviylj The outbreak of the novel coronavirus in China (SARS‐CoV‐2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID‐19 were enrolled. The median age was 47 years (interquartile range, 36‐55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty‐three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d‐dimer, lactate dehydrogenase, PCT, ALB, C‐reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID‐19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID‐19. shock. On 7 January 2019, scientists successfully isolated the pathogen that causes the pneumonia, a new type of β-coronavirus, and it was named 2019-nCoV. 1 Subsequently, WHO named it coronavirus disease . An epidemiological survey showed that the first occurrence of COVID-19 patients was closely related to a seafood market in south China. Due to the "Spring Festival Movement" (known as the "annual migration of the population in China"), COVID-19 rapidly spread throughout the country, and the number of infected people gradually increased. The spread of COVID-19 among people has been confirmed to occur through multiple channels, such as droplets, aerosols, feces, and mouth mucus membranes. 1 The aim of this study is to describe the epidemiological and clinical features, laboratory findings, radiological characteristics, treatment, and outcomes of COVID-19 patients in northeast Chongqing. It is hoped that these findings will assist the global community to more clearly understand and treat this new infectious disease. Clinical data of 135 COVID-19 patients were collected from 23 January 2020, when the first case in northeast Chongqing was found, to 8 February 2020. The research team collected the clinical data of patients using the electronic medical record system (HIS). General information included epidemiological histories, current medical histories, symptoms, physical signs, laboratory examination results, chest computed tomography (CT) manifestations, treatment measures, complications, admissions to intensive care unit (ICU), and other parameters. The patients were divided into mild (including normal and mild) and severe (including severe and critical) groups. The mild group had mild clinical symptoms and no pneumonia on imaging. The normal group had symptoms of fever, respiratory tract symptoms, and imaging showed pneumonia. The severe group had respiratory distress, RR ≥ 30 beats/minute in a resting state, a mean oxygen saturation of ≤93%, and an arterial blood oxygen partial pressure (PaO 2 )/oxygen concentration (FiO 2 ) ≤ 300 mm Hg. The critical group had respiratory failure and required mechanical ventilation, the occurrence of shock, and the combined failure of other organs that required ICU monitoring and treatment. 3 All of the suspected cases were detected using real-time reverse transcription polymerase chain reaction (PCR), and those who were positive for the coronavirus RNA were identified as confirmed cases. Throat swab samples of the patients were collected, and COVID-19 was de- The categorical variables were described as frequency rates and percentages, and the continuous variables were described using the mean, median, and interquartile range (IQR) values. The continuous variables were compared using independent group t tests when the data were normally distributed; otherwise, the Mann-Whitney test was used. The proportions of categorical variables were compared using a χ 2 test. All of the statistical analyses were performed using GraphPad Prism 8. For unadjusted comparisons, a two-sided α of less than .05 was considered to be statistically significant. The analyses were not adjusted for multiple comparisons, and given the potential for type I error, the findings should be interpreted as exploratory and descriptive. The marginal areas of the lesions were ill-defined. There was little pleural effusion, and consolidation of the lung occurred when the disease was serious (Figure 2 ). 6 This suggests that the virus may cause disease by attacking the immune system. LDH and aspartate aminotransferase generally increased, but the albumin of patients decreased. In addition, the changes in the severe patients were more obvious than the mild patients, suggesting that early liver function may be damaged in the mild patients, while liver damage in the severe patients was more obvious. Among the 135 patients, only 1 patient died, and this case will be briefly discussed. He was a 52-year-old male with diabetes and a chronic disease, and his son had recently returned from Wuhan. His neutrophil, D-dimer count, lymphocyte, CD4 + T, CD8 + T, B cell, and NK cell counts were above normal levels. In addition, his CD4 + T/CD8 + T counts continued to decline until death ( This study has several limitations. First, the sample size was relatively small compared to Wuhan, where the disease originated, which may have some impact on the statistical results. In general, the number of patients in this area is in the middle level of the rest of the country, except for Wuhan. Therefore, the research results were reliable. Second, most of the 135 patients were still hospitalized at the end of this study. Therefore, it was difficult to evaluate the risk factors for a poor prognosis. Long-term observation is required. In future research, a multicenter study will be established to expand the sample size and to conduct more rigorous randomized controlled trials. In addition, the follow-up of patients who were cured and discharged will be conducted. Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance General Office of the National Health and Family Planning Commission. Diagnosis and treatment of novel coronavirus pneumonia (trial version 5) Effects of matrine combied with baicalin on mouse pneumonia induced by LPS Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv Importation and human-tohuman transmission of a novel coronavirus in Vietnam Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study Severe acute respiratory syndrome: radiographic and CT findings Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR Expression of elevated levels of proinflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? On the use of corticosteroids for 2019-nCoV pneumonia SARS: systematic review of treatment effects Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia Application of Chinese medicine in acute and critical medical conditions Clinical features and treatment of COVID-19 patients in northeast Chongqing The authors declare that there are no conflict of interests. SW and YH had the idea for and designed the study and had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. SW, YX, YH, YZ, YX, WF, and BL contributed to writing of the report. SW and YH contributed to the statistical analysis. RY contributed to picture drawing.All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed and approved the final version. http://orcid.org/0000-0001-6591-053X